Yale opens center to study cannabis and cannabinoids

[CBD molecule courtesy of PubChem]

Yale School of Medicine has established a research center, the Yale Center for the Science of Cannabis and Cannabinoids, to investigate how cannabis and cannabinoids affect neurodevelopment and mental health. Led by Dr. Deepak Cyril D’Souza, an expert in cannabinoid pharmacology, the center will use a multidisciplinary approach to study the acute and chronic effects of these substances. 

Yale psychiatry chair Dr. John H. Krystal, and the university’s dean of medicine, Dr. Nancy J. Brown, announced the establishment of the new cannabinoids center on January 30, 2023. 

The two said the center’s opening was timely given the rapid commercialization of cannabis in the U.S. In addition to internal funding, the new center will intend to secure a P50-type center grant for further research.

Booming cannabinoids interest but relatively limited research


Read more
  • 0

Unlock advanced CBD formulations with nutritional lipids

Scientist pipetting samples into micro centrifuge tubes ready for automated analysis. Image courtesy of DSM.

Cannabidiol (CBD) is fast emerging as an exciting ingredient across the pharmaceutical market, powered by increasing scientific research investigating its potential benefits in a number of disease states, including central nervous system (CNS) disorders, pain management, cancer and more. While there is a remarkable opportunity for the development of CBD-based solutions in the field, formulation can be challenging at times, especially when the focus is on increasing the oral bioavailability of the molecule. There are new and emerging ways to address the technical challenges associated with CBD bioavailability and enable the molecule to fulfill its full potential as a therapeutic agent. Here, we explore how lipid-based systems may hold the key to success in this space.

Understanding the complexity of CBD f…
Read more
  • 0

Preclinical cannabinoid-based study found some benefits for autism spectrum disorder

Photo from Pexels

A preclinical study published in Nature indicates that cannabidiol (CBD)-enriched medical cannabis therapy may potentially bode well for autism spectrum disorder (ASD).

Researchers at Tel Aviv University determined that CBD-enriched cannabis therapy improved “repetitive and anxiety behaviors, but not social deficits” in mice with the autism-associated InsG3680 Shank3 mutation. The scientists also found that the treatment led to cerebellar changes in mRNA expression of several neurotransmission-related genes.

The scientists, however, questioned whether CBD enrichment of medical cannabis would be effective in treating core ASD symptoms, highlighting the possible role of tetrahydrocannabinol (THC) in treating ASD symptoms.

Interest in cannabis-based therapies for autism spectrum disorder has grown in recent years as consumer interest in CBD has exploded.

Rigorous medical d…

Read more
  • 0